missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ LETMD1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA5104399
This item is not returnable.
View return policy
Description
Antibody detects endogenous levels of total LETMD1.
HCCR-1 (human cervical cancer oncogene 1), also known as HCCR-2 or LETMD1, is a 360 amino acid single-pass membrane protein that is expressed in the kidney, liver, skeletal muscle, heart and brain. It is suggested that HCCR-1 may be involved in tumorigenesis and may function as a negative regulator of the p53 tumor suppressor. Overexpression of HCCR-1 may cause mitochondrial dysfunction that can lead to UVC or staurosporine-induced apoptosis resistance and progression of tumor formation. HCCR-1 is considered a candidate biomarker for breast cancer. Various human tumors including leukemia, lymphoma, and carcinomas of the breast, kidney, ovary, stomach, colon, and uterine cervix have high HCCR-1. Six isoforms exist due to alternative splicing events.
Specifications
| LETMD1 | |
| Polyclonal | |
| Unconjugated | |
| LETMD1 | |
| 1110019O13Rik; AI593524; BB130465; BB235638; Cervical cancer 1 proto-oncogene protein p40; cervical cancer proto-oncogene 2 protein; Cervical cancer receptor; HCCR1; HCCR-1; HCCR-2; HCRR-2; LETM1 domain containing 1; LETM1 domain-containing protein 1; LETMD1; MCC-32; Mccr; regulator of TP53; RGD1310591 | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 25875, 681352, 68614 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| Q6P1Q0, Q924L1 | |
| LETMD1 | |
| A synthesized peptide derived from human LETMD1(Accession Q6P1Q0), corresponding to amino acid residues T19-G69. | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction